Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIDEROS open-label extension of idebenone in Duchenne muscular dystrophy
NL-OMON48973Phase 3Active, not recruiting
- Sponsor
- Santhera Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of idebenone in Duchenne muscular dystrophy (DMD), sponsored by Santhera Pharmaceuticals. Primary endpoint: Long-term safety. Started Oct 2020; status: active, not recruiting.
02
Drugs
idebenone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON48973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48973.